VIVITROL

Opioid Use Disorder Market Insights, Epidemiology and Forecasts, 2019-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
General Health, Pharmaceutical, Health, FDA, United Kingdom, Naltrexone, Epidemiology, Naloxone, Expert Opinion on Emerging Drugs, Therapy, Medicare, Organ donation after medical assistance in dying, Opioid use disorder, VIVITROL, Community Living Assistance Services and Supports Act, OTP, Disease, Methadone, OUD, Growth, Medicaid, COVID-19, Drug, EU4, Vaccine, Cereal, Pharmaceutical industry, Medical device, Dentistry, Health insurance, Health care, Buprenorphine, Indivior

The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Key Points: 
  • The "Opioid Use Disorder (OUD)" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
  • The Opioid Use Disorder (OUD) market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Opioid Use Disorder (OUD) market size from 2019 to 2032.
  • Opioid Use Disorder (OUD) Treatment FDA-approved drugs such as Buprenorphine, methadone, and naltrexone have proven effective in treating Opioid Use Disorder, decreasing overdose rates.
  • Which type of Opioid Use Disorder (OUD), as per severity, is the largest contributor to the Opioid Use Disorder (OUD) patient pool?

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Retrieved on: 
Wednesday, August 30, 2023
1836 U.S. Patent Office fire, Patent, Orange, Teva, Justice, United States Department of Justice, Naltrexone, Federal Trade Commission, ALKS, Food and Drug Administration, Orange Book, Injunction, VIVITROL, District court, Alkermes, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Court, Douglas v. U.S. District Court ex rel Talk America, Generic drug

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Key Points: 
  • DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
  • Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No.
  • 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.
  • The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation

Retrieved on: 
Wednesday, August 30, 2023
1836 U.S. Patent Office fire, Patent, Orange, Teva, Justice, United States Department of Justice, Naltrexone, Federal Trade Commission, ALKS, Food and Drug Administration, Orange Book, Injunction, VIVITROL, District court, Alkermes, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Court, Douglas v. U.S. District Court ex rel Talk America, Generic drug

DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension). Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No. 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.

Key Points: 
  • DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into a settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") to resolve the ongoing patent litigation between the parties in the U.S. District Court for the District of New Jersey related to VIVITROL® (naltrexone for extended-release injectable suspension).
  • Pursuant to the terms of the settlement agreement, the company has granted Teva a license under U.S. Patent No.
  • 7,919,499 to market a generic version of VIVITROL in the United States beginning January 15, 2027, or earlier under certain customary circumstances.
  • The company and Teva will submit the settlement agreement for review to the United States Federal Trade Commission and the United States Department of Justice.

Alcohol Use Disorder Market to Witness Positive Growth at a CAGR of 8.8% by 2032 | DelveInsight

Retrieved on: 
Wednesday, September 28, 2022
Memantine, New, Social stigma, GHB, Perspiration, Compliance, ASP, Topiramate, Lists of diseases, Patient, Disulfiram, United Kingdom, Benzodiazepine, Astellas Pharma, National Institute, AUD, Psychiatric and mental health nursing, Prevalence, GABAB, Knowledge, Biomarker, Growth, Acamprosate, Alcoholism, Attention, Otsuka Pharmaceutical, Diagnostic and Statistical Manual of Mental Disorders, Drinking, ALKS, Health care, SMO, Gabapentin, Seizure, Corcept Therapeutics, Diagnosis, Hope, Population, Baclofen, Sodium oxybate, DSM, CORT, DSM-IV, LAS, VIVITROL, Mood Swings, National Institute on Alcohol Abuse and Alcoholism, Aripiprazole, Therapy, ALKS 3831, US FDA, DSM-V, Varenicline, Novo Nordisk, Pharmaceutical industry, Lithium, Alkermes, Ondansetron

LAS VEGAS, Sept. 28, 2022 /PRNewswire/ --DelveInsight's Alcohol Use Disorder Market Insights report includes a comprehensive understanding of current treatment practices, alcohol use disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

Key Points: 
  • Leading alcohol use disordercompanies such as Alkermes, Lundbeck, Otsuka Pharmaceuticals, Adial Pharmaceuticals, MediciNova, Corcept Therapeutics, Astellas Pharma, Bioprojet, and others are developing novel alcohol use disorder drugs that can be available in the alcohol use disorder market in the upcoming years.
  • DelveInsight estimates that there were approximately 25 million 12-month diagnosed prevalent cases of alcohol use disorder in the 7MM in 2021.
  • TOPAMAX (topiramate) is even recommended for alcohol use disorder treatment by the National Institute on Alcohol Abuse and Alcoholism.
  • Moreover, because of the change in alcohol use disorder diagnostic criteria from DSM-IV to DSM-V, country-specific epidemiologic data on diagnosis, severity, and treatment are scarce and thus limiting the alcohol use disorder market growth.

Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica

Retrieved on: 
Monday, November 8, 2021
Intellectual property, ALKS, View, Cancer, Nanocrystal, Private Securities Litigation Reform Act, Investor, Biogen, Government, U.S. Securities and Exchange Commission, Engineering, VIVITROL, Neurodegeneration, Bipolar I disorder, Growth, ARISTADA, COVID-19, Research, Schizophrenia, Multimedia, Annual report, Intention, Risk, Johnson & Johnson, SEC, Webcast, Review, Janssen, INVEGA, Wind, Time, Patent, Nasdaq, Uncertainty, FDA

DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal technology.

Key Points: 
  • DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal technology.
  • Pursuant to the agreements, the partial termination is to become effective three months from the date of receipt of the Notices.
  • Janssen maintains that it has not utilized, and does not utilize, Alkermes' NanoCrystal technology licensed under the agreements.
  • "For years, Janssen has highlighted the use of our NanoCrystal technology in its long-acting INVEGA products and has paid us know-how royalties consistent with this fact.

Alkermes Announces Receipt of Notices of Partial Termination From Janssen Pharmaceutica

Retrieved on: 
Monday, November 8, 2021
Intellectual property, ALKS, Cancer, Nanocrystal, Private Securities Litigation Reform Act, Investor, Biogen, Government, U.S. Securities and Exchange Commission, Engineering, VIVITROL, Neurodegeneration, Bipolar I disorder, Growth, ARISTADA, COVID-19, Research, Schizophrenia, Annual report, Intention, Risk, Conference, Johnson & Johnson, SEC, Webcast, Review, Janssen, INVEGA, Wind, Time, Patent, Nasdaq, Uncertainty, FDA

DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal® technology. The terminations impact know-how royalties related to sales of long-acting paliperidone products, such as INVEGA SUSTENNA® and INVEGA TRINZA®, and other products in the United States. Pursuant to the agreements, the partial termination is to become effective three months from the date of receipt of the Notices. Janssen maintains that it has not utilized, and does not utilize, Alkermes' NanoCrystal technology licensed under the agreements. Alkermes strongly disagrees with Janssen's position and will explore all options at its disposal to enforce its contractual rights and address any unauthorized use of its intellectual property.

Key Points: 
  • ET
    DUBLIN, Nov. 8, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received notices of partial termination (the "Notices") in respect of two license agreements with Janssen Pharmaceutica N.V. ("Janssen"), a subsidiary of Johnson & Johnson and, under these agreements, a licensee and recipient of Alkermes' nanoparticulate formulation technology, known as NanoCrystal technology.
  • Pursuant to the agreements, the partial termination is to become effective three months from the date of receipt of the Notices.
  • Janssen maintains that it has not utilized, and does not utilize, Alkermes' NanoCrystal technology licensed under the agreements.
  • "For years, Janssen has highlighted the use of our NanoCrystal technology in its long-acting INVEGA products and has paid us know-how royalties consistent with this fact.

Dr. Christopher DiGiulio Has Recently Opened His Bend Suboxone Treatment Clinic

Retrieved on: 
Tuesday, September 28, 2021
Temple University School of Medicine, Drug, Medical assistant, Policy, Edmund DiGiulio, Record, Addiction, Pains, MAT, Narcotic, Patient, Health, FDA, Substance abuse, Buprenorphine, Occupational medicine, Physician, Certification, MD, Oregon Department of Consumer and Business Services, VIVITROL, Federation, Topical steroid withdrawal, Death, Swelling, Program, Life, Female, Risk, Addiction medicine, Male, Oregon Department of Corrections, Naltrexone, Heroin, Practitioner, History, Food and Drug Administration, Urgent care center, Blister, State, Comprehensive Addiction and Recovery Act, Department, Pharmaceutical industry

BEND, Ore., Sept. 28, 2021 /PRNewswire-PRWeb/ -- Bend Suboxone is an addiction treatment clinic founded by Dr. Christopher DiGiulio.

Key Points: 
  • BEND, Ore., Sept. 28, 2021 /PRNewswire-PRWeb/ -- Bend Suboxone is an addiction treatment clinic founded by Dr. Christopher DiGiulio.
  • He is board-certified and has extensive expertise in treating substance abuse using state-of-the-art modalities including Suboxone and Vivitrol.
  • At Bend Suboxone clinic, patients can get access to Suboxone therapy.
  • At Bend Suboxone clinic, the addiction treatment doctors keep careful records of any other medications their patients take, their history with narcotics, and co-occurring illnesses they might have.